NCM USA   Report issue

For profit Phase 3
Founded: New York NY United States (2010)

Organization Overview

First Clinical Trial
2016
NCT03136328
First Marketed Drug
2014
sodium fluoride-18f
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

NCM USA BRONX LLC